TORL-1-23

Recent clinical trials demonstrate encouraging efficacy of CLDN6-directed antibody-drug conjugates DS-9606 and TORL-1-23 in treating various solid tumors, with response rates up to 50% in CLDN6-positive platinum-resistant ovarian cancer.

Pembrolizumab plus chemoradiotherapy significantly improved overall survival in high-risk locally advanced cervical cancer, establishing a new standard of care.

TORL-1-23 demonstrates clinically meaningful and durable responses in patients with Claudin 6 positive platinum-resistant ovarian cancer, with a manageable safety profile.

TORL-1-23, a CLDN6-targeted antibody-drug conjugate, demonstrates encouraging responses in heavily pretreated patients with advanced solid tumors, including platinum-resistant ovarian cancer.

TORL BioTherapeutics has raised $158 million in an oversubscribed Series B-2 financing round to support its antibody-drug conjugate (ADC) oncology pipeline.